OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

OncoCyte Corp. (NYSE-A:OCX) said its DetermaVu liquid biopsy test detected lung cancer with sensitivity of 90% and specificity of 75% in the prospective R&D Validation study in 250 patient blood samples.

OncoCyte said it will confirm sensitivity and specificity for the test in an additional validation study in 350 patient samples before it launches the product in the U.S. next half. OncoCyte President and CEO Bill Annett told BioCentury the company is developing the product under FDA's CLIA regulatory pathway...